These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30422368)

  • 1. Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics.
    Shimizu T; Nakayama Y; Ishii E; Ida S; Satou T; Tokuhara D; Arai K; Nii M; Rydholm H; Yajima T;
    Pediatr Int; 2019 Jan; 61(1):87-95. PubMed ID: 30422368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.
    Sandström M; Davidson G; Tolia V; Sullivan JE; Långström G; Lundborg P; Brown K
    Clin Ther; 2012 Aug; 34(8):1828-38. PubMed ID: 22832034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.
    Lou HY; Chang CC; Sheu MT; Chen YC; Ho HO
    Eur J Clin Pharmacol; 2009 Jan; 65(1):55-64. PubMed ID: 18751689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent Gastric Acid Inhibition Over 24 Hours by 4-Times Daily Dosing of Esomeprazole 20 mg.
    Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Kagami T; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
    Digestion; 2015; 91(4):277-85. PubMed ID: 25924819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
    Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
    Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response.
    Earp JC; Mehrotra N; Peters KE; Fiorentino RP; Griebel D; Lee SC; Mulberg A; Röhss K; Sandström M; Taylor A; Tornøe CW; Wynn EL; Van der Walt JS; Garnett C
    J Pediatr Gastroenterol Nutr; 2017 Sep; 65(3):272-277. PubMed ID: 27875488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.
    Kagami T; Sahara S; Ichikawa H; Uotani T; Yamade M; Sugimoto M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2016 May; 43(10):1048-59. PubMed ID: 26991399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early effects of oral administration of esomeprazole and omeprazole on the intragastric pH.
    Iida H; Inamori M; Okuno K; Sekino Y; Sakai E; Okubo H; Higurashi T; Endo H; Hosono K; Yoneda M; Koide T; Takahashi H; Goto A; Kubota K; Saito S; Maeda S; Nakajima A; Gotoh E
    Hepatogastroenterology; 2015; 62(138):493-6. PubMed ID: 25916088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
    Schwab M; Klotz U; Hofmann U; Schaeffeler E; Leodolter A; Malfertheiner P; Treiber G
    Clin Pharmacol Ther; 2005 Dec; 78(6):627-34. PubMed ID: 16338278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis.
    Lovell DJ; Dare JA; Francis-Sedlak M; Ball J; LaMoreaux BD; Von Scheven E; Reinhardt A; Jerath R; Alpan O; Gupta R; Goldsmith D; Zeft A; Naddaf H; Gottlieb B; Jung L; Holt RJ
    Pediatr Rheumatol Online J; 2018 Jun; 16(1):41. PubMed ID: 29941047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Tolerability of Esomeprazole in Children With Gastroesophageal Reflux Disease.
    Gilger MA; Tolia V; Vandenplas Y; Youssef NN; Traxler B; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S16-23. PubMed ID: 26422093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
    Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Tolerability of Esomeprazole in Children With Gastroesophageal Reflux Disease.
    Gilger MA; Tolia V; Vandenplas Y; Youssef NN; Traxler B; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S16-23. PubMed ID: 26121345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
    Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
    Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: a five-way crossover study.
    Yang H; Li J; Zhao Q; Li J; Shen K; Yang X; Jiang J; Hu P; Qian J
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1823-8. PubMed ID: 23800161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease.
    Omari T; Davidson G; Bondarov P; Nauclér E; Nilsson C; Lundborg P
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S2-8. PubMed ID: 26422094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease.
    Omari T; Davidson G; Bondarov P; Nauclér E; Nilsson C; Lundborg P
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S2-8. PubMed ID: 26121346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes.
    Nagase M; Shimada H; Nii M; Ueda S; Higashimori M; Ichikawa K; Zhang L; Zhou L; Chen Y; Zhou D; Dunyak J; Al-Huniti N
    J Clin Pharm Ther; 2020 Oct; 45(5):1030-1038. PubMed ID: 32227647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study.
    Zhao J; Li J; Hamer-Maansson JE; Andersson T; Fulmer R; Illueca M; Lundborg P
    Clin Ther; 2006 Nov; 28(11):1868-76. PubMed ID: 17213007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control.
    Wang H; Shao F; Liu X; Xu W; Ou N; Qin X; Liu F; Hou X; Hu H; Jiang J
    Br J Clin Pharmacol; 2019 Nov; 85(11):2547-2558. PubMed ID: 31332820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.